Paclitaxel Administered Weekly in Patients with Docetaxel-Resistant Metastatic Breast Cancer: A Single-Center Study

Author:

Sawaki Masataka12,Ito Yoshinori1,Hashimoto Daigo3,Mizunuma Nobuyuki1,Takahashi Shunji1,Horikoshi Noboru1,Tada Keiichiro4,Kasumi Fujio4,Akiyama Futoshi5,Sakamoto Goi5,Imai Tsuneo2,Nakao Akimasa2,Hatake Kiyohiko1

Affiliation:

1. Department of Medical Oncology, Cancer Institute Hospital and Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo

2. Second Department of Surgery, Nagoya University School of Medicine, Nagoya

3. Second Department of Medicine, Okayama University Medical School, Okayama

4. Department of Breast Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo

5. Department of Breast Pathology, Japanese Foundation for Cancer Research, Tokyo, Japan

Abstract

Aims and background We evaluated retrospectively the efficacy and toxicity of paclitaxel in patients with docetaxel-resistant metastatic breast cancer. Study design Paclitaxel (80 mg/m2) was administered weekly to 44 patients who had previously received chemotherapy regimens for metastatic breast cancer. All patients had progressive disease in spite of having received docetaxel therapy. Results Treatment was repeated until there was evidence of disease progression. Objective responses were obtained in 14 of 44 assessable patients (31.8%; 95% confidence interval, 17.5–46.1). Fourteen patients had partial responses; none responded completely. Seven of 14 responders had primary resistance to docetaxel therapy. The median duration of response was 6.1 months (range, 2.1–12.7). The median time to progression was 5.0 months. Clinically severe adverse events (grade 3 or 4) included neutropenia (27.2%), leukopenia (25.0%), neuropathy-sensory (13.6%), febrile neutropenia (6.8%), anemia (2.2%), constipation (2.2%), and edema (2.2%). Treatment was generally well tolerated and could be continued on an out-patient basis. Conclusions Weekly paclitaxel is effective in patients with docetaxel-resistant metastatic breast cancer. This observation suggests partial cross-resistance between paclitaxel and docetaxel. There was no evidence for additive cumulative toxic effects of the two taxanes.

Publisher

SAGE Publications

Subject

Cancer Research,Oncology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3